Antifibrotic therapy

In two of three phase 3 trials, Pirfenidone ( Esbriet ), an oral antifibrotic therapy, reduced disease progression, as measured...


Pirfenidone ( Esbriet ) is a novel antifibrotic drug for the treatment of mild-to-moderate idiopathic pulmonary fibrosis ( IPF )....